Raymond James Maintains Outperform Rating for Neurocrine Biosciences: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Raymond James has maintained its Outperform rating for Neurocrine Biosciences (NASDAQ:NBIX) and increased its price target from $135.00 to $145.00. This new target price represents a potential 30.7% increase from the current share price. Neurocrine Biosciences is a pharmaceutical company with three late-stage clinical programs.
November 01, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James has maintained its Outperform rating for Neurocrine Biosciences and raised its price target, indicating a positive outlook for the company's stock.
The maintained Outperform rating and increased price target by Raymond James indicates a positive outlook for Neurocrine Biosciences. This could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100